Why Israel Leads Global Cannabis Extract Growth through Medical Research and Export Strength
Israel posts a 12.0% CAGR through 2036, propelled by world‑class medical research and export‑oriented production. Fact.MR cites advanced extraction technologies that serve both domestic therapies and international pharmaceutical markets.
Strict regulatory oversight and export licensing guarantee consistent quality, positioning Israel as the scientific benchmark for cannabis extracts.
How Canada Maintains Market Leadership through Comprehensive Legalization and Scale
Canada records a 17.7% CAGR through 2036, thanks to its fully legalized federal framework and a network of licensed producers scaling extraction capacity. The Cannabis Act provides clear regulatory pathways that sustain growth.
Integrated supply chains, regulated retail, rising medical registrations and strong recreational demand keep Canada at the forefront of the global market.
How the United States Drives Cannabis Extract Growth amid State‑Level Legalization
The U.S. market expands at an 11.3% CAGR, driven by expanding state medical and recreational legalization and a growing patient base. Fact.MR notes multi‑state operators increasing extraction capacity despite fragmented regulations.
Expectations of federal reform and continued state adoption sustain long‑term growth, while pharmaceutical cannabinoid development and FDA‑approved therapies add momentum.
Why the United Kingdom Emerges as a Structured Medical Cannabis Market
The UK’s 11.2% CAGR reflects rising prescriptions and integration into consultant‑led care pathways, primarily in specialist clinics and private practices for treatment‑resistant conditions. Fact.MR attributes growth to import licensing and pharma distribution partnerships.
Clinician‑research collaborations build robust evidence, reinforcing demand for pharmaceutical‑grade extracts.
How Australia Supports Market Growth through Controlled Medical Frameworks
Australia achieves an 11.1% CAGR, powered by the Therapeutic Goods Administration’s regulated framework and expanding prescriber access via the Special Access Scheme. Specialty pharmacies and medical practitioners drive demand for high‑quality extracts.
Structured regulation ensures patient safety and clinical evidence, supporting consistent market expansion.
Why Germany Leads European Cannabis Extract Adoption through Insurance Coverage
Germany’s 11.0% CAGR stems from statutory health insurance reimbursement and pharmacy‑based dispensing of extracts prescribed for chronic pain and approved indications. Fact.MR highlights established pharma wholesalers and strict quality standards.
These factors make Germany a central hub for European medical cannabis development.
How Brazil Develops Cannabis Extract Demand through Regulatory Progress
Brazil’s 10.9% CAGR reflects evolving ANVISA regulations and growing patient advocacy, with access centered on import authorization and compassionate‑use programs in major urban regions. Fact.MR notes patient associations and specialist physicians driving adoption for chronic and severe conditions.
Gradual regulatory progress creates early‑stage opportunities for cannabis extract therapies.
